NMRA

MKT CAP:$405M

Neumora Therapeutics, Inc. Common Stock

Market Cap

$405M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.27+$0.61 (+36.75%)

Apr 23, 2026

Company Details

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140)...

CEO

Daljit Singh Aurora

IPO Date

Sep 15, 2023

Website

www.neumoratx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$237M

EPS (Diluted)

-$1.45

Free Cash Flow

-$206M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$1.45

Q4 2025

Mar 30, 2026

$0EPS -$0.35

Q3 2025

Nov 6, 2025

$0EPS -$0.35

Q2 2025

Aug 6, 2025

$0EPS -$0.33

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$43M
Q2 22	$0	$0	-$31M
Q3 22	$0	$0	-$31M
Q4 22	$0	$0	-$31M
Q1 23	$0	$0	-$39M
Q2 23	$0	$0	-$42M
Q3 23	$0	$0	-$57M
Q4 23	$0	-$166.0K	-$50M
Q1 24	$0	$0	-$60M
Q2 24	$0	$0	-$64M
Q3 24	$0	$0	-$77M
Q4 24	$0	$0	-$63M
Q1 25	$0	$0	-$71M
Q2 25	$0	$0	-$54M
Q3 25	$0	-$5M	-$58M
Q4 25	$0	$0	-$58M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$32M	-$32M
Q2 22	-$27M	-$27M
Q3 22	-$26M	-$26M
Q4 22	-$30M	-$30M
Q1 23	-$33M	-$33M
Q2 23	-$31M	-$31M
Q3 23	-$48M	-$48M
Q4 23	-$51M	-$51M
Q1 24	-$43M	-$43M
Q2 24	-$56M	-$56M
Q3 24	-$33M	-$33M
Q4 24	-$50M	-$50M
Q1 25	-$59M	-$59M
Q2 25	-$52M	-$52M
Q3 25	-$47M	-$47M
Q4 25	-$48M	-$48M

Capital Expenditures

Quarter	CapEx
Q1 22	$176.0K
Q2 22	$182.0K
Q3 22	$130.0K
Q4 22	$23.0K
Q1 23	$36.0K
Q2 23	$0
Q3 23	$37.0K
Q4 23	$44.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$16.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+179.9%
Q2 22	—	+82.1%
Q3 22	—	-82.8%
Q4 22	—	+15.7%
Q1 23	—	-9.4%
Q2 23	—	+34.3%
Q3 23	—	+85.8%
Q4 23	—	+63.1%
Q1 24	—	+53.4%
Q2 24	—	+51.7%
Q3 24	—	+34.8%
Q4 24	—	+25.6%
Q1 25	—	+18.1%
Q2 25	—	-15.3%
Q3 25	—	-24.7%
Q4 25	—	-7.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$0	—
Q3 22	$2M	—
Q4 22	$3M	—
Q1 23	$2M	—
Q2 23	$0	—
Q3 23	$6M	—
Q4 23	$6M	—
Q1 24	$7M	—
Q2 24	$13M	—
Q3 24	$10M	—
Q4 24	$10M	—
Q1 25	$9M	—
Q2 25	$7M	—
Q3 25	$6M	—
Q4 25	$7M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$35M	$8M	—
Q2 22	$24M	$8M	—
Q3 22	$23M	$8M	—
Q4 22	$24M	$7M	—
Q1 23	$29M	$10M	—
Q2 23	$33M	$9M	—
Q3 23	$42M	$15M	—
Q4 23	$39M	—	$11M
Q1 24	$46M	$14M	—
Q2 24	$49M	$15M	—
Q3 24	$61M	$16M	—
Q4 24	$46M	$17M	—
Q1 25	$52M	$19M	—
Q2 25	$39M	$15M	—
Q3 25	$41M	$12M	—
Q4 25	$45M	$14M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$409M	$0	$409M
Q1 22	$291M	$58M	$350M
Q2 22	$174M	$153M	$328M
Q4 22	$241M	$131M	$372M
Q1 23	$211M	$135M	$346M
Q2 23	$204M	$120M	$324M
Q3 23	$412M	$97M	$510M
Q4 23	$374M	$80M	$454M
Q1 24	$183M	$240M	$423M
Q2 24	$151M	$221M	$372M
Q3 24	$276M	$66M	$341M
Q4 24	$142M	$165M	$308M
Q1 25	$127M	$122M	$249M
Q2 25	$125M	$93M	$218M
Q3 25	$129M	$42M	$172M
Q4 25	$183M	$0	$183M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	152M	0.0%	0.0%
Q2 22	152M	+0.0%	+0.0%
Q3 22	152M	-0.0%	0.0%
Q4 22	152M	0.0%	0.0%
Q1 23	152M	0.0%	0.0%
Q2 23	152M	+0.0%	0.0%
Q3 23	155M	+2.3%	+2.3%
Q4 23	159M	+2.2%	+4.5%
Q1 24	158M	-0.6%	+3.9%
Q2 24	159M	+0.7%	+4.6%
Q3 24	160M	+0.4%	+2.7%
Q4 24	161M	+0.9%	+1.4%
Q1 25	161M	+0.3%	+2.2%
Q2 25	162M	+0.1%	+1.7%
Q3 25	162M	+0.1%	+1.4%
Q4 25	163M	+1.0%	+1.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	124
Q1 24	$0	124
Q2 24	$0	124
Q3 24	$0	124
Q4 24	$0	110
Q1 25	$0	110
Q2 25	$0	110
Q3 25	$0	110
Q4 25	$0	200K

Revenue / Employee